350 related articles for article (PubMed ID: 15226679)
1. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Okuda M; Tanaka K; Inui K
Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
[TBL] [Abstract][Full Text] [Related]
2. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients.
Uesugi M; Masuda S; Katsura T; Oike F; Takada Y; Inui K
Pharmacogenet Genomics; 2006 Feb; 16(2):119-27. PubMed ID: 16424824
[TBL] [Abstract][Full Text] [Related]
3. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation.
Goto M; Masuda S; Saito H; Uemoto S; Kiuchi T; Tanaka K; Inui K
Pharmacogenetics; 2002 Aug; 12(6):451-7. PubMed ID: 12172213
[TBL] [Abstract][Full Text] [Related]
4. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients.
Fukudo M; Yano I; Masuda S; Goto M; Uesugi M; Katsura T; Ogura Y; Oike F; Takada Y; Egawa H; Uemoto S; Inui K
Clin Pharmacol Ther; 2006 Oct; 80(4):331-45. PubMed ID: 17015051
[TBL] [Abstract][Full Text] [Related]
7. Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients.
Masuda S; Goto M; Okuda M; Ogura Y; Oike F; Kiuchi T; Tanaka K; Inui K
Transplant Proc; 2005 May; 37(4):1728-9. PubMed ID: 15919446
[TBL] [Abstract][Full Text] [Related]
8. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
9. Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.
Rahsaz M; Azarpira N; Nikeghbalian S; Aghdaie MH; Geramizadeh B; Moini M; Banihashemi M; Darai M; Malekpour Z; Malekhosseini SA
Exp Clin Transplant; 2012 Feb; 10(1):24-9. PubMed ID: 22309416
[TBL] [Abstract][Full Text] [Related]
10. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
Vannaprasaht S; Reungjui S; Supanya D; Sirivongs D; Pongskul C; Avihingsanon Y; Tassaneeyakul W
Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms.
Miyata Y; Akamatsu N; Sugawara Y; Kaneko J; Yamamoto T; Suzuki H; Arita J; Sakamoto Y; Hasegawa K; Tamura S; Kokudo N
Ann Transplant; 2016 Aug; 21():491-9. PubMed ID: 27503662
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients.
Li D; Lu W; Zhu JY; Gao J; Lou YQ; Zhang GL
J Clin Pharm Ther; 2007 Oct; 32(5):505-15. PubMed ID: 17875118
[TBL] [Abstract][Full Text] [Related]
15. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients.
Uesugi M; Hosokawa M; Shinke H; Hashimoto E; Takahashi T; Kawai T; Matsubara K; Ogawa K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Biol Pharm Bull; 2013; 36(11):1814-21. PubMed ID: 24189425
[TBL] [Abstract][Full Text] [Related]
16. Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period.
Zhang X; Wang Z; Fan J; Liu G; Peng Z
Eur J Clin Pharmacol; 2011 Aug; 67(8):803-13. PubMed ID: 21359536
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Influence of CYP3A5 Gene Polymorphism on Pharmacokinetics of Tacrolimus and Patient Outcome After Living Donor Liver Transplantation.
Kato H; Usui M; Muraki Y; Tanemura A; Murata Y; Kuriyama N; Azumi Y; Kishiwada M; Mizuno S; Sakurai H; Okuda M; Nakatani K; Isaji S
Transplant Proc; 2016 May; 48(4):1087-94. PubMed ID: 27320564
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
Tsuchiya N; Satoh S; Tada H; Li Z; Ohyama C; Sato K; Suzuki T; Habuchi T; Kato T
Transplantation; 2004 Oct; 78(8):1182-7. PubMed ID: 15502717
[TBL] [Abstract][Full Text] [Related]
20. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]